NeoPharm CO. LTD (092730) - Net Assets
Based on the latest financial reports, NeoPharm CO. LTD (092730) has net assets worth ₩188.40 Billion KRW (≈ $127.68 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩207.38 Billion ≈ $140.54 Million USD) and total liabilities (₩18.97 Billion ≈ $12.86 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 092730 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩188.40 Billion |
| % of Total Assets | 90.85% |
| Annual Growth Rate | 15.96% |
| 5-Year Change | 50.26% |
| 10-Year Change | 442.2% |
| Growth Volatility | 19.93 |
NeoPharm CO. LTD - Net Assets Trend (2012–2024)
This chart illustrates how NeoPharm CO. LTD's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of NeoPharm CO. LTD for the complete picture of this company's asset base.
Annual Net Assets for NeoPharm CO. LTD (2012–2024)
The table below shows the annual net assets of NeoPharm CO. LTD from 2012 to 2024. For live valuation and market cap data, see 092730 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩176.88 Billion ≈ $119.87 Million |
+10.54% |
| 2023-12-31 | ₩160.03 Billion ≈ $108.45 Million |
+12.53% |
| 2022-12-31 | ₩142.21 Billion ≈ $96.37 Million |
+9.14% |
| 2021-12-31 | ₩130.30 Billion ≈ $88.31 Million |
+10.69% |
| 2020-12-31 | ₩117.72 Billion ≈ $79.78 Million |
+11.38% |
| 2019-12-31 | ₩105.69 Billion ≈ $71.63 Million |
+78.27% |
| 2018-12-31 | ₩59.29 Billion ≈ $40.18 Million |
+24.60% |
| 2017-12-31 | ₩47.58 Billion ≈ $32.25 Million |
+23.36% |
| 2016-12-31 | ₩38.57 Billion ≈ $26.14 Million |
+18.23% |
| 2015-12-31 | ₩32.62 Billion ≈ $22.11 Million |
+9.02% |
| 2012-12-31 | ₩29.92 Billion ≈ $20.28 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NeoPharm CO. LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 845.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩130.57 Billion | 73.82% |
| Other Components | ₩46.32 Billion | 26.18% |
| Total Equity | ₩176.88 Billion | 100.00% |
NeoPharm CO. LTD Competitors by Market Cap
The table below lists competitors of NeoPharm CO. LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LUOYANG GLASS CO. H YC 1
F:LUG
|
$110.48 Million |
|
Borosil Scientific
NSE:BOROSCI
|
$110.49 Million |
|
WW Holding Inc
TW:8442
|
$110.54 Million |
|
Crosswood
PA:CROS
|
$110.58 Million |
|
Union Bankshares Inc
NASDAQ:UNB
|
$110.44 Million |
|
Affluent Medical SAS
PA:AFME
|
$110.43 Million |
|
Nova Klúbburinn hf.
IC:NOVA
|
$110.40 Million |
|
SAMYOUNG M-Tek Co. Ltd
KQ:054540
|
$110.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NeoPharm CO. LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 160,025,953,680 to 176,884,836,520, a change of 16,858,882,840 (10.5%).
- Net income of 23,064,751,600 contributed positively to equity growth.
- Dividend payments of 5,865,471,000 reduced retained earnings.
- Share repurchases of 36,411,560 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩23.06 Billion | +13.04% |
| Dividends Paid | ₩5.87 Billion | -3.32% |
| Share Repurchases | ₩36.41 Million | -0.02% |
| Other Changes | ₩-303.99 Million | -0.17% |
| Total Change | ₩- | 10.54% |
Book Value vs Market Value Analysis
This analysis compares NeoPharm CO. LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.80x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.74x to 1.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩5452.10 | ₩20400.00 | x |
| 2017-12-31 | ₩6725.83 | ₩20400.00 | x |
| 2018-12-31 | ₩8380.41 | ₩20400.00 | x |
| 2019-12-31 | ₩13514.59 | ₩20400.00 | x |
| 2020-12-31 | ₩15052.18 | ₩20400.00 | x |
| 2021-12-31 | ₩16661.69 | ₩20400.00 | x |
| 2022-12-31 | ₩18184.06 | ₩20400.00 | x |
| 2023-12-31 | ₩20462.03 | ₩20400.00 | x |
| 2024-12-31 | ₩11308.86 | ₩20400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NeoPharm CO. LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.04%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 19.38%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.09x
- Recent ROE (13.04%) is below the historical average (15.42%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 2.16% | 3.45% | 0.55x | 1.14x | ₩-2.34 Billion |
| 2015 | 10.44% | 9.47% | 0.89x | 1.24x | ₩144.78 Million |
| 2016 | 20.07% | 18.27% | 0.91x | 1.21x | ₩3.89 Billion |
| 2017 | 24.29% | 21.55% | 0.95x | 1.19x | ₩6.80 Billion |
| 2018 | 25.92% | 23.19% | 0.91x | 1.23x | ₩9.44 Billion |
| 2019 | 18.21% | 23.12% | 0.68x | 1.16x | ₩8.68 Billion |
| 2020 | 15.40% | 22.21% | 0.61x | 1.13x | ₩6.36 Billion |
| 2021 | 13.59% | 20.14% | 0.61x | 1.10x | ₩4.68 Billion |
| 2022 | 11.97% | 20.02% | 0.55x | 1.09x | ₩2.81 Billion |
| 2023 | 14.51% | 23.90% | 0.55x | 1.11x | ₩7.21 Billion |
| 2024 | 13.04% | 19.38% | 0.62x | 1.09x | ₩5.38 Billion |
Industry Comparison
This section compares NeoPharm CO. LTD's net assets metrics with peer companies in the Personal & Household Products & Services industry.
Industry Context
- Industry: Personal & Household Products & Services
- Average net assets among peers: $56,541,543,983
- Average return on equity (ROE) among peers: 9.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NeoPharm CO. LTD (092730) | ₩188.40 Billion | 2.16% | 0.10x | $110.44 Million |
| Globon Co. Ltd (019660) | $17.61 Billion | 23.84% | 0.76x | $44.74 Million |
| HYUNDAI BIOLAND Co.Ltd (052260) | $135.98 Billion | 5.92% | 0.35x | $46.66 Million |
| Gentrogroup Co. Ltd. (083660) | $16.03 Billion | 0.00% | 1.17x | $5.82 Million |
About NeoPharm CO. LTD
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELE… Read more